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Introduction
CXCL13 (BCA-1, BLC), a chemokine constitutively
expressed by cells in secondary lymphoid organs, pro-
motes the chemotaxis of B cells to secondary lymphoid
organs. There is accumulating evidence that CXCL13 is
aberrantly expressed in a variety of lymphomas; thus we
sought to define the longitudinal expression pattern of
CXCL13 preceding a non-Hodgkin’s lymphoma (NHL)
diagnosis in the setting of HIV.
Methods
A nested case-control study was conducted in the setting
of two large prospective cohort studies of the natural and
treated history of HIV and AIDS, the Multicenter AIDS
Cohort Study (MACS) and the Women’s Interagency HIV
Study (WIHS). Archival, pre-cancer diagnosis serum speci-
mens from NHL cases (180 MACS and 30 WIHS) and
HIV-seropositive matched controls (180 MACS and 109
WIHS) were assayed for CXCL13 by ELISA. Visit-matched
sera from case-control pairs were obtained when available
from three time windows preceding NHL diagnosis in the
case: 3-5 years pre-NHL (closest to 4 years), 1-3 years pre-
NHL (closest to 2 years), and 0-1 year pre-NHL (closest to
0.5 year). These data were analyzed using multivariate
conditional logistic regression models to obtain adjusted
odds ratios (OR) and 95% confidence intervals (95% CI)
for each unit increase in log-transformed CXCL13 for
each of the three study visits.
Results
CXCL13 levels were significantly elevated at all three
time points preceding the clinical recognition of NHL,
3-5 years: OR=3.66 (95% CI, 2.34-5.74); 1-3 years:
OR=6.62 (95% CI, 3.78-11.6); and 0-1 year: OR=3.68
(95% CI, 2.27-5.98). Subgroup analyses revealed that
CXCL13 was more strongly associated with systemic
NHL compared to central nervous system NHL, and
EBV-negative compared to EBV-positive tumors.
Conclusions
These data suggest that CXCL13 may be a biomarker
for NHL in the setting of HIV, and is more strongly
associated with systemic, EBV-negative tumors. Studies
are currently under way to further characterize the role
CXCL13, and its receptor CXCR5, in lymphomagenesis.
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